List of Excipients in Branded Drug CHLORPHENIRAMINE MALEATE

Generic Drugs Containing CHLORPHENIRAMINE MALEATE

Company	Ingredient	NDC	Excipient
Cardinal Health Inc	chlorpheniramine maleate	37205-117	CALCIUM SULFATE
Cardinal Health Inc	chlorpheniramine maleate	37205-117	CARNAUBA WAX
Cardinal Health Inc	chlorpheniramine maleate	37205-117	CELLULOSE, MICROCRYSTALLINE
Cardinal Health Inc	chlorpheniramine maleate	37205-117	D&C YELLOW NO. 10
Cardinal Health Inc	chlorpheniramine maleate	37205-117	FD&C BLUE NO. 2
Cardinal Health Inc	chlorpheniramine maleate	37205-117	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in CHLORPHENIRAMINE MALEATE?

# Of NDCs	Excipient
1	CALCIUM SULFATE
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 2
1	FD&C YELLOW NO. 6

Chlorpheniramine Maleate Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Chlorpheniramine maleate is an old, low-cost first-generation antihistamine with no meaningful molecule-level patent barrier in the United States. Commercial value now depends on formulation differentiation, regulatory positioning, dosage-form convenience, supply reliability, and combination-product design. The strongest opportunities are in orally disintegrating tablets, low-sugar liquids, pediatric dosing systems, extended-release products, and fixed-dose combinations that comply with FDA OTC monograph requirements.

What is the current commercial and regulatory status of chlorpheniramine maleate?

Chlorpheniramine maleate is an FDA-recognized antihistamine used for temporary relief of allergic rhinitis symptoms, including sneezing, runny nose, and itchy or watery eyes. It is marketed primarily in oral tablets, extended-release tablets or capsules, oral solutions, and combination cold products.[1,2]

The active pharmaceutical ingredient is the maleate salt of chlorpheniramine, commonly supplied as a racemic mixture. A standard immediate-release tablet contains 4 mg of chlorpheniramine maleate. Extended-release products commonly contain 8 mg or 12 mg, depending on the product and labeling.

Attribute	Commercial position
Active ingredient	Chlorpheniramine maleate
Therapeutic class	First-generation H1 antihistamine
Primary uses	Allergic rhinitis and temporary relief of cold symptoms
Common immediate-release strength	4 mg
Common dosage forms	Tablets, chewable tablets, liquids, extended-release tablets or capsules
U.S. regulatory pathway	OTC monograph and abbreviated or legacy drug-product pathways, depending on product
Orange Book relevance	Product-specific; no meaningful new-molecule exclusivity
Biosimilar exposure	None; chlorpheniramine is a small molecule
Core commercial issue	Price competition and formulation differentiation

FDA’s OTC monograph framework permits certain antihistamine products to be marketed without a product-specific premarket approval when the formulation, active ingredient, dosage, labeling, and conditions of use conform to the applicable monograph.[1]

When does chlorpheniramine maleate lose patent exclusivity?

Chlorpheniramine maleate lost practical compound-level exclusivity decades ago. The active ingredient has been used in commercial medicines since the mid-20th century, and generic and private-label products are widely available.

There is no commercially important basic composition-of-matter patent blocking routine chlorpheniramine maleate products. Any remaining patent risk would arise from a particular formulation, delivery system, combination, manufacturing process, or branded product rather than from the active ingredient itself.

Patent and exclusivity profile

IP category	Current commercial significance
Basic compound patent	Expired
Salt-form protection	Expired or commercially irrelevant
Immediate-release tablet patents	Generally expired
Standard liquid formulation patents	Generally expired
Extended-release technology	May be protected in some historical products, but broad blocking rights are unlikely
Combination-product patents	Potentially relevant for novel combinations or delivery systems
Trademark rights	Relevant for brand positioning, not active-ingredient exclusivity
Regulatory exclusivity	No current new chemical entity exclusivity

The absence of molecule-level exclusivity does not eliminate freedom-to-operate analysis. A manufacturer entering a branded extended-release or combination product should review active patents covering release-control matrices, dosing schedules, flavor systems, child-resistant packaging, and other formulation-specific features.

What patents protect chlorpheniramine maleate products?

Current commercial protection is primarily product-specific and formulation-specific. Routine 4 mg immediate-release tablets generally have limited patent exposure because the dosage form, strength, and use are conventional.

Potentially relevant patent categories include:

1. Extended-release dosage forms using hydrophilic or hydrophobic matrices.
2. Multiparticulate beads or coated pellets.
3. Orally disintegrating tablets with taste-masking systems.
4. Liquid formulations with improved palatability or reduced precipitation.
5. Fixed-dose combinations with decongestants, antitussives, or analgesics.
6. Unit-dose delivery devices and metered liquid systems.
7. Pediatric formulations with dosing safeguards.
8. Stabilized formulations designed for longer shelf life.

A patent search should focus on the exact product architecture rather than the active ingredient alone. Claims directed to chlorpheniramine in broad combination with conventional excipients are often vulnerable to prior-art challenges. Claims tied to a defined dissolution profile, particle coating, excipient ratio, taste-masking mechanism, or manufacturing step may have greater durability.

How strong is the chlorpheniramine maleate patent estate?

The patent estate is weak for conventional immediate-release products and stronger only where a manufacturer has created a technically differentiated delivery system.

Product strategy	Patent strength	Commercial barrier
Standard 4 mg tablet	Low	Manufacturing scale and price
Chewable tablet	Low to moderate	Taste masking and sensory performance
Oral solution	Low	Palatability, preservative system, packaging
Orally disintegrating tablet	Moderate	Disintegration, taste, moisture protection
Extended-release product	Moderate	Dissolution profile and historical patents
Pediatric unit-dose liquid	Low to moderate	Device design, safety, labeling
Novel combination product	Moderate to high	Clinical, regulatory, and patent complexity
Transdermal or nonoral delivery	Potentially high	Development cost and regulatory burden

The strongest defensible position generally comes from a combination of formulation claims, process claims, and trade secrets covering excipient selection, coating parameters, scale-up, and sensory performance.

What excipients are used in chlorpheniramine maleate tablets?

Immediate-release tablets typically use a conventional solid-dose excipient system. The active ingredient is present at a low dose, so content uniformity and blend segregation are important development issues.

Common excipient classes include:

Function	Representative excipients
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Magnesium stearate, sodium stearyl fumarate
Glidant	Colloidal silicon dioxide
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants
Sweetener for chewables	Sucralose, aspartame, acesulfame potassium, saccharin sodium
Flavor	Mint, cherry, grape, orange, or proprietary flavor systems

The final formula must be based on the selected supplier grade, process, target dissolution, tablet hardness, moisture sensitivity, and labeling requirements. Commercial product labels show that excipient composition varies substantially by manufacturer.[2]

Excipient selection priorities

For a standard tablet, the main technical risks are low-dose uniformity, sticking during compression, rapid but controlled disintegration, and acceptable tablet robustness. A direct-compression platform using microcrystalline cellulose, a high-functionality disintegrant, and a low-concentration lubricant can reduce process complexity.

For wet granulation, the formulation team should control exposure to water and drying temperature. Chlorpheniramine maleate is generally compatible with conventional oral solid-dose processing, but salt form, particle size, and moisture exposure can affect blend behavior and dissolution.

What excipient strategies support commercial differentiation?

Taste masking for chewable and orally disintegrating products

Chlorpheniramine maleate has a bitter pharmaceutical taste. Taste masking is therefore a major opportunity in pediatric and convenience formats.

Potential approaches include:

• Polymer-coated drug particles.
• Ion-exchange resin complexes.
• Lipid or wax matrices.
• Spray-dried dispersions.
• Cyclodextrin complexes.
• Sweetener and flavor systems optimized through human sensory testing.

Taste masking must not materially delay dissolution after swallowing. A product that performs well in a laboratory dissolution test but leaves bitterness during disintegration can fail commercially.

Low-sugar and sugar-free liquids

Sugar-free products can target adults managing sugar intake and parents seeking pediatric formulations. Common systems may use sorbitol, glycerin, propylene glycol, sucralose, or other permitted sweeteners and humectants.

The formulation must address:

• Viscosity and dose-measurement accuracy.
• Preservative efficacy.
• pH stability.
• Flavor stability.
• Crystallization or precipitation.
• Compatibility with plastic bottles and dosing syringes.

A low-sugar product can command a modest premium if it improves taste and provides a reliable dosing device. The opportunity is stronger when paired with a clean-label or allergen-positioning strategy, subject to applicable regulatory and substantiation limits.

Orally disintegrating tablets

Orally disintegrating tablets can differentiate chlorpheniramine through portability and ease of administration. Mannitol-based systems are common because they provide cooling mouthfeel and acceptable compressibility. Crospovidone, low-substituted hydroxypropyl cellulose, and optimized porous structures can support rapid disintegration.

The principal barriers are moisture uptake, friability, tablet packaging, and bitterness. Aluminum-aluminum blister packaging may improve stability but increases packaging cost.

Extended-release systems

Extended-release chlorpheniramine products can reduce dosing frequency and create a stronger product identity than generic immediate-release tablets. Hydrophilic matrices based on hypromellose are a common development route. Coated multiparticulates can provide more precise release control and reduce dose-dumping risk.

The commercial value depends on whether the product obtains a clinically and regulatorily meaningful dosing advantage. A formulation that merely changes tablet architecture without improving adherence, tolerability, or convenience may not support premium pricing.

What formulation patents could protect a new chlorpheniramine product?

A defensible patent strategy should claim measurable technical attributes rather than the use of ordinary excipients in generic proportions.

Potential claim targets include:

1. A defined extended-release dissolution profile.
2. A coated-particle architecture with specified polymer layers.
3. A taste-masked formulation with a defined bitterness threshold.
4. A low-moisture orally disintegrating tablet with specified disintegration time.
5. A liquid formulation with improved chemical stability over a defined pH range.
6. A preservative system that maintains microbial control without compromising palatability.
7. A combination of chlorpheniramine and another active ingredient with improved dose uniformity.
8. A manufacturing process that reduces segregation or coating variability.

Patent claims should be supported by comparative data against conventional formulations. Useful evidence includes dissolution profiles, accelerated stability, sensory testing, content-uniformity data, tablet friability, dose-delivery accuracy, and scale-up reproducibility.

What FDA regulatory pathway applies to chlorpheniramine maleate products?

For U.S. OTC products, the principal pathway is conformity with the applicable FDA OTC monograph and general requirements for labeling, manufacturing, quality, and packaging.[1]

A product that falls outside the monograph may require an FDA-approved new drug application or another applicable regulatory route. Changes involving strength, route of administration, active-ingredient combination, dosing schedule, or disease claims can move a product outside ordinary monograph conditions.

Important regulatory controls include:

• Drug Facts labeling.
• Age-based dosing.
• Sedation and impairment warnings.
• Combination-product labeling.
• Child-resistant packaging where required.
• Current good manufacturing practice compliance.
• Stability and microbial control for liquids.
• Accurate measuring devices for pediatric products.

Chlorpheniramine can cause drowsiness and anticholinergic effects. Those characteristics affect labeling, product positioning, and the commercial viability of daytime versus nighttime formulations.[1,2]

What is the Orange Book status of chlorpheniramine maleate?

The Orange Book is most relevant to approved prescription drug products and certain abbreviated applications. Conventional OTC monograph products do not rely on Orange Book exclusivity in the same way as innovator prescription products.

There is no meaningful current Orange Book exclusivity barrier associated with the chlorpheniramine molecule itself. Product-level listings, if applicable to a specific approved product, must be reviewed by product number and dosage form. The practical entry barrier for a new OTC chlorpheniramine product is formulation execution, regulatory compliance, branding, distribution, and cost rather than Orange Book exclusivity.[3]

Are there Paragraph IV challenges or generic litigation risks?

Paragraph IV litigation is not a central risk for conventional OTC monograph chlorpheniramine products. A Paragraph IV certification applies to an abbreviated application that references listed patents. Most standard chlorpheniramine products compete without a meaningful active patent estate.

Litigation risk can arise in narrower circumstances:

• An ANDA references an approved extended-release product with listed formulation patents.
• A branded combination product has active patent listings.
• A manufacturer asserts trade-dress or trademark rights.
• A formulation patent claims a specific release profile or coating system.
• A product sponsor alleges misappropriation of manufacturing know-how.

The expected litigation risk for a basic immediate-release 4 mg tablet is low. The risk increases with extended-release products and proprietary combination products.

What generic launch scenarios exist for chlorpheniramine maleate?

Immediate-release tablet launch

This is the lowest-risk and lowest-margin scenario. A manufacturer can compete through:

• Low-cost supply.
• Private-label retail distribution.
• Contract manufacturing.
• Smaller pack sizes.
• Multi-pack and club-store formats.
• Basic tablet, chewable, or liquid variants.

Price competition is severe because multiple suppliers can manufacture conventional tablets.

Premium OTC formulation launch

A premium strategy could use an orally disintegrating tablet, improved taste, sugar-free liquid, or unit-dose pediatric package. The product requires stronger consumer positioning and retailer acceptance but may support higher gross margins.

Combination-product launch

Combination products can expand the addressable market through allergy, cold, nighttime, or cough-and-cold positioning. They also introduce more complex labeling, active-ingredient compatibility, regulatory review, and potential safety scrutiny.

Extended-release launch

An extended-release product can target once- or twice-daily dosing and may obtain stronger brand differentiation. Development costs and patent review are higher, while consumer demand depends on a clear convenience benefit.

Which companies compete in chlorpheniramine maleate products?

Competition includes branded OTC companies, generic drug manufacturers, private-label suppliers, and contract manufacturers. Historical and current market participants have included products sold under Chlor-Trimeton, Coricidin, generic store brands, and combination cold-product labels.[2]

The competitive landscape is fragmented:

Segment	Typical competitor type	Competitive basis
4 mg tablets	Generic and private-label manufacturers	Lowest unit cost
Liquids	OTC brands and pediatric suppliers	Taste, dosing, packaging
Chewables	Branded OTC and specialty suppliers	Flavor and convenience
Extended-release	Branded or specialty manufacturers	Dosing frequency
Combination products	Large OTC companies	Shelf placement and brand recognition
Institutional supply	Contract and generic manufacturers	Reliability and price

Manufacturer-level opportunity is strongest where a supplier can combine low-cost API sourcing with differentiated packaging or dosage-form technology.

What licensing opportunities exist for chlorpheniramine maleate?

Licensing opportunities are more likely to involve formulation platforms than the active ingredient. Relevant deal structures may include:

• Licensing an orally disintegrating tablet platform.
• Acquiring a taste-masking technology.
• Partnering with a pediatric liquid manufacturer.
• Licensing extended-release coating technology.
• Supplying a branded private-label formulation.
• Combining chlorpheniramine with a proprietary delivery device.
• Granting regional rights for OTC distribution.

Because the API is commoditized, a licensing deal based solely on chlorpheniramine maleate has limited strategic value. A licensor needs to offer one of four assets: regulatory-ready product, protected formulation, differentiated consumer brand, or reliable low-cost manufacturing.

How does chlorpheniramine compare with competing antihistamines?

Attribute	Chlorpheniramine	Cetirizine	Loratadine	Diphenhydramine
Generation	First	Second	Second	First
Sedation risk	Material	Lower for many users	Generally lower	Material
Typical positioning	Allergy and cold products	Allergy	Non-drowsy allergy	Allergy and nighttime products
Formulation opportunity	Taste masking, ER, liquids	Chewables, liquids, ODTs	ODTs, liquids, combinations	Nighttime and sleep-adjacent products
Price pressure	Very high	High	High	Very high
Differentiation potential	Moderate through format	Moderate through convenience	Moderate through branding	Moderate through nighttime positioning

Chlorpheniramine’s main disadvantage is sedation. Its advantages are low API cost, long commercial history, established consumer recognition, and suitability for combination products. Excipient innovation cannot eliminate the pharmacologic sedation risk, but it can improve palatability, dosing convenience, stability, and adherence.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are modest for immediate-release tablets but more substantial for differentiated products.

Key barriers include:

• Consistent low-dose content uniformity.
• Control of API particle size and flow.
• Taste-masking coating uniformity.
• Moisture protection for ODTs.
• Dissolution control for extended-release products.
• Liquid preservative efficacy.
• Accurate pediatric dose delivery.
• Packaging compatibility and child resistance.
• Reliable API supply and impurity control.

Trade secrets may provide more practical protection than patents in this market. Coating conditions, flavor ratios, granulation endpoints, and packaging configurations can be difficult for competitors to reproduce even when the patent estate is weak.

What is the revenue exposure and commercial opportunity?

Public revenue data usually aggregates chlorpheniramine within broader OTC allergy or cold portfolios rather than reporting the ingredient separately. The molecule is unlikely to support a premium standalone business based on active-ingredient exclusivity.

The most attractive revenue pools are:

1. Retail private-label products with high-volume manufacturing.
2. Sugar-free and pediatric liquids.
3. Orally disintegrating and chewable tablets.
4. Extended-release products with clear dosing advantages.
5. Seasonal allergy and nighttime combination products.
6. Regional licensing and contract-manufacturing arrangements.

The commercial model is volume-driven for standard tablets and margin-driven for differentiated formulations. Retail distribution, seasonal inventory planning, and brand placement may have greater impact on returns than patent term.

Key Takeaways

• Chlorpheniramine maleate has no meaningful current compound-level exclusivity.
• Conventional 4 mg immediate-release tablets are low-risk but highly price competitive.
• The strongest excipient opportunities are taste masking, sugar-free liquids, ODTs, pediatric delivery systems, and extended-release matrices.
• Formulation patents should claim measurable technical performance, not ordinary excipient combinations.
• Paragraph IV and Orange Book risks are limited for standard OTC monograph products.
• Biosimilar risk is irrelevant because chlorpheniramine is a small-molecule drug.
• Licensing value lies in formulation technology, regulatory-ready products, branding, or manufacturing scale.
• Commercial success depends on dosage-form convenience, sensory performance, distribution, and supply economics.

FAQs About Chlorpheniramine Maleate Formulation and Commercialization

Can chlorpheniramine maleate be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, taste-masking polymers, and moisture-protective packaging are potential components of an ODT platform. The product must balance rapid disintegration, low friability, acceptable mouthfeel, and bitterness control.

Which excipient is best for chlorpheniramine maleate taste masking?

No single excipient is universally preferred. Polymer coating, ion-exchange resins, lipid systems, and cyclodextrins can be evaluated. Selection depends on dissolution, bitterness duration, process cost, and stability.

Is chlorpheniramine maleate suitable for pediatric liquid products?

Yes, but pediatric liquids require careful control of flavor, viscosity, preservative efficacy, dose-measurement accuracy, and age-specific labeling. A calibrated oral syringe can provide a commercial advantage over household-spoon dosing.

Can a new chlorpheniramine formulation receive patent protection?

Potentially. Protection is more credible for a formulation with demonstrated technical performance, such as a defined release profile, improved taste masking, superior stability, or a proprietary delivery system.

Does chlorpheniramine maleate have biosimilar competition?

No. Biosimilars apply to biological products. Chlorpheniramine maleate is a conventional small-molecule active ingredient and competes through generic and OTC pathways.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/

2. National Library of Medicine. (2024). DailyMed: Chlorpheniramine maleate drug labels. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book